Skip to main content
Premium Trial:

Request an Annual Quote

Rubicon, Kreatech Sign Amplification Tech Agreement

NEW YORK (GenomeWeb News) – Rubicon Genomics has signed an agreement to provide Kreatech Diagnostics with its OmniPlex-D whole-genome amplification technology.

Under the agreement, Rubicon will provide Kreatech with reagents incorporating elements of the OmniPlex technology, which Kreatech will use in the manufacture of its Poseidon fluorescence in situ hybridization probes. Financial and other terms of the agreement were not disclosed.

The OmniPlex technology has been designed to "deliver sufficient quantities of high-quality species-specific or locus-specific RNA or DNA to increase the sensitivity and specificity of analyses of biological samples for biomedical research and clinical medicine," Ann Arbor, Mich.-based Rubicon said in a statement.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.